RegulatoryJul 10, 2026, 08:37 AM
Autonomix Medical Regains Nasdaq Bid Price Compliance
AI Summary
Autonomix Medical, Inc. announced it has regained compliance with the Nasdaq Capital Market's minimum bid price requirement. The company previously received a deficiency letter on January 14, 2026, for its common stock trading below $1.00 per share. On July 9, 2026, Nasdaq confirmed that Autonomix Medical had met the Bid Price Rule by maintaining a closing bid price of $1.00 or more for 10 consecutive business days, from June 24, 2026, through July 8, 2026.
Key Highlights
- Autonomix Medical received a deficiency letter on January 14, 2026, for failing to meet Nasdaq's $1.00 bid price rule.
- The deficiency was under Nasdaq Listing Rule 5550(a)(2).
- On July 9, 2026, the company was notified it had regained compliance with the Bid Price Rule.
- Compliance was achieved by maintaining a closing bid price of $1.00 or more for 10 consecutive business days.
- The 10-day compliance period was from June 24, 2026, through July 8, 2026.
Price Impact
More from AMIX